BOSTON (USA) – Saïdal Group Marketing Director Naili Saad-Eddine Yahia, said Saturday in Boston (USA) that the insulin produced in Constantine will be available on the national market in the first half of 2016.
On the sidelines of the 75th Session of the American Diabetes Association, the same official said that Constantine insulin production plant will start from the first half of 2016 the production of insulin in vials or in the form of pens.
He added that insulin production, as part of the partnership concluded in 2014 between Group Saïdal and Danish laboratory Novo Nordisk, aims primarily to meet national needs in insulin. The plant will produce three million units in vials and 7 million units in pens to later export, he added.
Naili announced the production of 200 kinds of new drugs for the treatment of chronic diseases, including diabetes and cardiovascular diseases.
In this context, he recalled that the goal from Saidal participation in this scientific meeting is to be informed about the new treatments and scientific progress in the field of diabetes, especially as the treatment of this disease is included in its strategic plan of care for chronic diseases.
According to different studies by the Ministry of Health, Population and Hospital Reform, 10 to 12% of the population suffer from type 2 diabetes.